The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
The Ministry of Health, Labor and Welfare (MHLW) plans to set up in FY2020 a new study group on the reporting system of inappropriate detailing activities by sales reps from all medical institutions and pharmacies, which started in October. The…
To read the full story
Related Article
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- MHLW Wants to Encourage Non-Monitoring Facilities to Report Inappropriate Drug Promotion
January 29, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- MHLW Sets Up New Office to Take Reports on Inappropriate Detailing Activities from Healthcare Providers
October 3, 2019
- MHLW Planning to Launch Report System on Inappropriate Detailing Activity as Early as Summer
May 21, 2019
REGULATORY
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…